David Hung, M.D., is the President and CEO of Nuvation Bio, a biotechnology company focused on innovative treatments. He has a strong background in the medical field, holding an M.D. from a recognized medical school and over 20 years of...
David Hung, M.D., is the President and CEO of Nuvation Bio, a biotechnology company focused on innovative treatments. He has a strong background in the medical field, holding an M.D. from a recognized medical school and over 20 years of experience in biopharmaceuticals. Under his leadership, the company has seen significant growth in both projects and value. Notably, his compensation in 2023 reached $4.32 million, largely driven by stock options, which tie his financial success to the company's performance. Intriguingly, in 2021, Dr. Hung's insider trading activity peaked at over $740 million in holdings, reflecting a high level of confidence in the company's future. He emphasizes aligning executive pay with company performance, showing a commitment to the shareholders' interests as well. Additionally, not only is he steering the company, but he is also contributing to governance by taking on the role of Chair on the Board, which gives him substantial influence over strategic decisions. David Hung is not just leading; he is also shaping the future of biopharma at Nuvation.